Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-20T09:30:39.239Z Has data issue: false hasContentIssue false
  • English
  • Français

Post-marketing surveillance (Phase IV drug studies)

A statement from the Research Committee

Published online by Cambridge University Press:  02 January 2018

C. P. Freeman
C. P. Freeman*
Affiliation:
Research Committee, Royal College of Psychiatrists
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Several College members have been in touch with the Research Committee asking for advice on the conduct of Phase IV trials. This topic has been extensively debated at the Research Committee, and we thought it would be helpful to members to have some guidance notes.

Type
The College
Information
Psychiatric Bulletin , Volume 18 , Issue 2 , February 1994 , pp. 115 - 116
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1994
Submit a response

eLetters

No eLetters have been published for this article.